Literature DB >> 8770711

Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection.

J P Hester1, M C Dignani, E J Anaissie, H M Kantarjian, S O'Brien, E J Freireich.   

Abstract

Fifteen patients with prolonged neutropenia (a median of 23 days with granulocyte [PMN] < or = 500/microliters) and established fungal infections that had not responded to adequate antifungal therapy were transfused with PMN concentrates collected from 35 cytokine-primed granulocyte colony-stimulating factor (GCSF) donors. Patients received a median of six transfusions. Leukocytosis and granulocytosis were observed within 24 hours of the first GCSF injection, which yielded concentrates averaging 55 x 10(9) white blood cells and 41 x 10(9) PMN. Data analysis suggested that response might be related to the duration of neutropenia and known infection, as patients given PMN tx earlier in the infectious course tended to have a better response. No significant toxicity was observed in donors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8770711     DOI: 10.1002/jca.2920100406

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  11 in total

1.  Does granulocyte transfusion play a role in the multidisciplinary treatment of invasive mycosis?

Authors:  Simone Cesaro; Piero Marson
Journal:  Support Care Cancer       Date:  2006-10-12       Impact factor: 3.603

Review 2.  Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience.

Authors:  Sameer S Kadri; Kenneth E Remy; Jeffrey R Strich; Juan Gea-Banacloche; Susan F Leitman
Journal:  Transfusion       Date:  2015-04-09       Impact factor: 3.157

3.  Gravity sedimentation of granulocytapheresis concentrates with hydroxyethyl starch efficiently removes red blood cells and retains neutrophils.

Authors:  Barbara J Bryant; Yu Ying Yau; Phyllis J Byrne; David F Stroncek; Susan F Leitman
Journal:  Transfusion       Date:  2010-01-22       Impact factor: 3.157

Review 4.  Granulocyte transfusion in the G-CSF era.

Authors:  Thomas H Price
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Rhino-orbital-cerebral mucormycosis.

Authors:  Maria N Gamaletsou; Nikolaos V Sipsas; Emmanuel Roilides; Thomas J Walsh
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 6.  Granulocyte transfusions in the management of invasive fungal infections.

Authors:  Kamille A West; Juan Gea-Banacloche; David Stroncek; Sameer S Kadri
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

7.  Collection by a simple bag method and the function of granulocytes in granulocyte transfusion.

Authors:  Kenji Nemoto; Atsushi Kikuta; Hitoshi Ohto; Hideki Sano; Masaki Itoh; Hitoshi Suzuki
Journal:  Int J Hematol       Date:  2006-07       Impact factor: 2.490

8.  Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection.

Authors:  Thomas H Price; Michael Boeckh; Ryan W Harrison; Jeffrey McCullough; Paul M Ness; Ronald G Strauss; W Garrett Nichols; Taye H Hamza; Melissa M Cushing; Karen E King; Jo-Anne H Young; Eliot Williams; Janice McFarland; Jennifer Holter Chakrabarty; Steven R Sloan; David Friedman; Samir Parekh; Bruce S Sachais; Joseph E Kiss; Susan F Assmann
Journal:  Blood       Date:  2015-09-02       Impact factor: 22.113

9.  Analysis of hematologic parameters of donors, patients, and granulocyte concentrates to predict successful granulocyte transfusion.

Authors:  Jong-Mi Lee; Seung Jun Choi; Hoon Seok Kim; Mina Yang; Yonggoo Kim; Jong Wook Lee; Jihyang Lim
Journal:  Blood Res       Date:  2019-03-21

Review 10.  Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies.

Authors:  Chiara Cugno; Sara Deola; Perla Filippini; David F Stroncek; Sergio Rutella
Journal:  J Transl Med       Date:  2015-11-16       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.